BTIG Keeps Their Buy Rating on Monopar Therapeutics Inc (MNPR)
BTIG analyst Jeet Mukherjee reiterated a Buy rating on Monopar Therapeutics Inc with a $104 price target. The stock closed at $87.01, and analysts have a consensus Strong Buy rating with a $110.33 price target, suggesting a 26.80% upside. Barclays also reiterated a Buy rating with a $125 target. Mukherjee, a 4-star analyst, has a 19.4% average return and a 71.43% success rate.
In a report released yesterday, Jeet Mukherjee from BTIG reiterated a Buy rating on Monopar Therapeutics Inc, with a price target of $104.00. The company’s shares closed yesterday at $87.01.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
According to TipRanks, Mukherjee is a 4-star analyst with an average return of 19.4% and a 71.43% success rate. Mukherjee covers the Healthcare sector, focusing on stocks such as Monopar Therapeutics Inc, Perspective Therapeutics, and Kymera Therapeutics.
Monopar Therapeutics Inc has an analyst consensus of Strong Buy, with a price target consensus of $110.33, implying a 26.80% upside from current levels. In a report released yesterday, Barclays also reiterated a Buy rating on the stock with a $125.00 price target.
